To describe the impact of a multidisciplinary tumor board (MTB) for renal cell carcinoma (RCC) patients in a locoregional renal cancer network by evaluating shared decision making (SDM) and adherence to MTB recommendations. This prospective cohort study included all cases from a Dutch renal cancer network with suspicion of or histologically confirmed RCC discussed in MTBs between 2017-2022. Main endpoints were distribution of cases presented, proportion of recommendations with multiple treatment options enabling shared decision making (SDM), definite treatment after SDM and adherence to MTB recommendations. Further endpoints were definite treatment per tumor stage stratified by age and inclusion in clinical trials. Outcomes were displayed as means and proportions (%). Pearson's Chi-Squared test was used to analyze the effect of age on definite treatment advice. Overall, 2651 cases were discussed, of which 1900 (72%) were new referrals and 751 (28%) rediscussions. Majority of cases were cT1a-b tumors (46%) and 22% were local recurrences or metachronous metastatic. Adherence to MTB recommendation was 96% and in 30% multiple treatment options were recommended, allowing for SDM. In 45% of cases with cT1a tumors multiple treatment options were recommended by the MTB, resulting in (cryo)ablation (32%) and AS (30%) as most frequent definite treatments after SDM. Among patients with cT3-4 tumors the inclusion rate in clinical trials was 47%. A network MTB creates opportunity to discuss multiple treatment options and clinical trials in SDM with patients at a high rate of adherence to MTB recommendation.

中文翻译：

---

多学科肿瘤委员会 (MTB) 对肾细胞癌 (RCC) 患者治疗决策的影响：5 年数据分析

通过评估共同决策 (SDM) 和对 MTB 建议的遵守情况，描述多学科肿瘤委员会 (MTB) 对局部肾癌网络中肾细胞癌 (RCC) 患者的影响。这项前瞻性队列研究纳入了 2017 年至 2022 年 MTB 中讨论的荷兰肾癌网络中怀疑或组织学证实的 RCC 的所有病例。主要终点是所呈现病例的分布、支持共享决策 (SDM) 的多种治疗方案的建议比例、SDM 后的明确治疗以及对 MTB 建议的遵守情况。进一步的终点是按年龄分层的每个肿瘤阶段的明确治疗和临床试验的纳入。结果显示为平均值和比例（%）。使用皮尔逊卡方检验分析年龄对明确治疗建议的影响。总体而言，讨论了 2651 例，其中 1900 例（72%）为新转诊，751 例（28%）为重新讨论。大多数病例为 cT1a-b 肿瘤（46%），22% 为局部复发或异时转移。 96% 的人遵守 MTB 建议，30% 的人建议采用多种治疗方案，从而允许 SDM。在 45% 的 cT1a 肿瘤病例中，MTB 推荐了多种治疗方案，其中（冷冻）消融 (32%) 和 AS (30%) 是 SDM 后最常见的明确治疗方法。在 cT3-4 肿瘤患者中，临床试验的纳入率为 47%。网络 MTB 创造了机会，与高度遵守 MTB 建议的患者讨论 SDM 的多种治疗方案和临床试验。